Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in Asia
The purpose of this study is to evaluate the efficacy and the safety of KHK7580 orally administered once daily for 52 weeks compared to cinacalcet hydrochloride as an active control in subjects with secondary hyperparathyroidism receiving hemodialysis in China, Korea, Hong Kong and Taiwan.
Secondary Hyperparathyroidism
DRUG: KHK7580|DRUG: Cinacalcet Hydrochloride
Mean percent change in intact parathyroid hormone (PTH) level from baseline in the evaluation period, Week 50- Week 52
Number of subjects achieving a mean intact PTH level of ≧150pg/mL and ≦300pg/mL in the evaluation period, Week 50- Week 52|Percentage of subjects achieving a mean intact PTH level of ≧150pg/mL and ≦300pg/mL in the evaluation period, Week 50- Week 52|Number of subjects achieving a mean percent decrease in intact PTH level of ≧３０% (percent change ≦-３０%) from baseline in the evaluation period, Week 50- Week 52|Percentage of subjects achieving a mean percent decrease in intact PTH level of ≧３０% (percent change ≦-３０%) from baseline in the evaluation period, Week 50- Week 52|Intact PTH level, Week 50- Week 52|corrected serum Ca level, Week 50- Week 52|serum P level, Week 50- Week 52
The purpose of this study is to evaluate the efficacy and the safety of KHK7580 orally administered once daily for 52 weeks compared to cinacalcet hydrochloride as an active control in subjects with secondary hyperparathyroidism receiving hemodialysis in China, Korea, Hong Kong and Taiwan.